ProVen VCT (LON:PVN) Reaches New 12-Month Low - What's Next?

Key Points

• ProVen VCT shares hit a new 52-week low — the stock traded as low as GBX 56.50 on Tuesday, down about 3.4% with roughly 205,695 shares changing hands.
• Valuation and technicals — market cap £165.54 million with a P/E of 19.48, and the share price is trading below both its 50‑day (GBX 58.70) and 200‑day (GBX 58.83) simple moving averages.
• Business profile and recent results — ProVen is a venture capital trust focused on emerging growth‑stage UK SMEs (not startups), reporting quarterly EPS of GBX 0.20, a net margin of 73.18% and a return on equity of 1.48%.

ProVen VCT (LON:PVN - Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as GBX 56.50 and last traded at GBX 56.50, with a volume of 205695 shares changing hands. The stock had previously closed at GBX 58.50.

ProVen VCT Stock Down 3.4%

The firm has a market cap of £165.54 million, a P/E ratio of 19.48 and a beta of 0.02. The firm's 50-day simple moving average is GBX 58.70 and its 200 day simple moving average is GBX 58.83.

ProVen VCT (LON:PVN - Get Free Report) last announced its quarterly earnings data on Tuesday, January 6th. The company reported GBX 0.20 EPS for the quarter. ProVen VCT had a net margin of 73.18% and a return on equity of 1.48%.

About ProVen VCT

ProVen VCT plc is a venture capital trust specializing in emerging growth stage investment,expansion and management buyouts. The fund invests in small and medium sized smaller companies. It does not invest in startups. It seeks to invest in non-qualifying investments including cash, liquidity funds, fixed interest securities, debt and debt related securities in growth companies and non-qualifying venture capital investments. It invests in unquoted and AIM-listed companies and SMEs based in United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.